Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients
-
Mahshid Movahedi
,
Masoud Movahedi
,
Nima Parvaneh
,
Hassan Abolhassani
,
Mohadese Mahdavi
,
Mohadese sadat Mosavikhorshidi
,
Fatemeh Alizadeh
,
Mehdi Shokri
,
Arash Kalantari
Abstract
Patients with inborn errors of immunity (IEI) are among the high-risk groups regarding COVID-19. Receiving booster doses (third and fourth) in addition to the standard doses is recommended in these patients. This study investigated the antibody response before and after a booster dose of Sinopharm vaccine in IEI patients.
Thirty patients (>12 years) with antibody deficiencies, referred to Imam Khomeini Hospital and Children's Medical Center in Tehran, were enrolled in this prospective cross-sectional study. All patients were fully vaccinated with the BBIBP-CorV vaccine (2 doses of Sinopharm). Initial measurements of anti-receptor-binding domain (anti-RBD) and anti-nucleocapsid (anti-N) IgG antibody responses were conducted by enzyme-linked immunosorbent assay (ELISA). Subsequently, all patients received a booster dose of the vaccine. Four to six weeks after booster injection, the levels of antibodies were re-evaluated.
Twenty patients with common variable immunodeficiency (CVID), 7 cases with agammaglobulinemia and 3 patients with hyper IgM syndrome were studied. Anti-RBD IgG and anti-N IgG antibodies increased in all patients after the booster.
Our results indicated the need of receiving booster doses of the COVID-19 vaccine in patients with antibody deficiencies, even for enhancing humoral immune response specially in patients with CVID.
1. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Rev. 2020;7(6):1012-23.
2. Giardino G, Romano R, Coppola E, Cillo F, Borzachiello C, De Luca M, et al. SARS-CoV-2 infection in the immunodeficient host: necessary and dispensable immune pathways. J Clin Immunol. 2021;9(9):3237-48.
3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020;181(2):271-80. e8.
4. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-80.
5. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood, The Journal of the American Society of Hematology. 2020;136(25):2881-92.
6. Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105(1):37-55.
7. Ma J, Cheng ZJ, Xue M, Huang H, Li S, Fang Y, et al. Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation. Fronti Immunol. 2022;13:913732.
8. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35-45.
9. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New Eng J Med. 2021;384(15):1412-23.
10. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572-7.
11. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Eng J Med. 2021;384(5):403-16.
12. Wood P, Stanworth S, Burton J, Jones A, Peckham D, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Expe Immunol. 2007;149(3):410-23.
13. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42(7):1473-507.
14. Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508-20.
15. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Clin Immunol. 2021;147(2):520-31.
16. Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. J Clin Immunol. 2021;9(7):2904-6. e2.
17. Ainsua-Enrich E, Pedreño-Lopez N, Bracke C, Ávila-Nieto C, de la Concepcion MLR, Pradenas E, et al. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals. Iscience. 2022;25(11).
18. Allan M, Lièvre M, Laurenson-Schafer H, de Barros S, Jinnai Y, Andrews S, et al. The World Health Organization COVID-19 surveillance database. Int J Equity Health. 2022;21(Suppl 3):167.
19. Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Clin Immunol. 2016;4(6):1066-75.
20. Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74.
21. Delmonte OM, Bergerson JR, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Clin Immunol. 2021;148(5):1192-7.
22. Pulvirenti F, Fernandez Salinas A, Milito C, Terreri S, Piano Mortari E, Quintarelli C, et al. B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies. Cells. 2021;10(11):2915.
23. Di Fusco M, Moran MM, Cane A, Curcio D, Khan F, Malhotra D, et al. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Eco. 2021;24(1):1248-60.
24. Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. J Clin Immunol. 2022;149(3):907-11. e3.
25. Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L, Li H, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. 2022;22(1):1584.
26. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity. J Clin Immunol. 2019;7(6):1763-70.
27. Zeng T, Lu Y, Zhao Y, et al. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts. Respir Res. 2023;24(1):246.
28. Salinas AF, Mortari EP, Terreri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. J Clin Immunol. 2021;41:1709-22.
29. Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R, Almendro-Vázquez P, Carretero O, Gil-Etayo FJ, et al. Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency. J Clin Immunol. 2022;42(2):240-52.
30. Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850.
31. Gernez Y, Murugesan K, Cortales CR, Banaei N, Hoyte L, Pinsky BA, et al. Immunogenicity of a third COVID-19 messenger RNA vaccine dose in primary immunodeficiency disorder patients with functional B-cell defects. J Allergy Clinical Immunol. 2022;10(5):1385-8. e2.
32. Goda V, Kriván G, Kulcsár A, Gönczi M, Tasnády S, Matula Z, et al. Specific antibody and the T-cell response elicited by BNT162b2 boosting after two ChAdOx1 nCoV-19 in common variable immunodeficiency. Front Immunol. 2022;13:907125.
33. Nourizadeh M, Feizabadi E, Mirmoghtadaei M, Mohammadi A, Fazlollahi MR, Moradi L, et al. Antibody production after COVID-19 vaccination in patients with inborn errors of immunity. 2023;20(4):400-9.
34. Squire J, Joshi A. Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency. Annals Allergy Asthma Immunol. 2021;127(3):383-4.
35. Delmonte OM, Castagnoli R, Notarangelo LD. COVID-19 and inborn errors of immunity. Physiology. 2022;37(6):290-301.
36. Shin JJ, Par-Young J, Unlu S, McNamara A, Park H-J, Shin MS, et al. Defining clinical and immunological predictors of poor immune responses to COVID-19 mRNA vaccines in patients with primary antibody deficiency. J Clin Immunol. 2022;42(6):1137-50.
2. Giardino G, Romano R, Coppola E, Cillo F, Borzachiello C, De Luca M, et al. SARS-CoV-2 infection in the immunodeficient host: necessary and dispensable immune pathways. J Clin Immunol. 2021;9(9):3237-48.
3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020;181(2):271-80. e8.
4. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-80.
5. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood, The Journal of the American Society of Hematology. 2020;136(25):2881-92.
6. Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105(1):37-55.
7. Ma J, Cheng ZJ, Xue M, Huang H, Li S, Fang Y, et al. Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation. Fronti Immunol. 2022;13:913732.
8. Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35-45.
9. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New Eng J Med. 2021;384(15):1412-23.
10. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572-7.
11. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Eng J Med. 2021;384(5):403-16.
12. Wood P, Stanworth S, Burton J, Jones A, Peckham D, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Expe Immunol. 2007;149(3):410-23.
13. Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42(7):1473-507.
14. Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508-20.
15. Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Clin Immunol. 2021;147(2):520-31.
16. Milito C, Lougaris V, Giardino G, Punziano A, Vultaggio A, Carrabba M, et al. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. J Clin Immunol. 2021;9(7):2904-6. e2.
17. Ainsua-Enrich E, Pedreño-Lopez N, Bracke C, Ávila-Nieto C, de la Concepcion MLR, Pradenas E, et al. Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individuals. Iscience. 2022;25(11).
18. Allan M, Lièvre M, Laurenson-Schafer H, de Barros S, Jinnai Y, Andrews S, et al. The World Health Organization COVID-19 surveillance database. Int J Equity Health. 2022;21(Suppl 3):167.
19. Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Clin Immunol. 2016;4(6):1066-75.
20. Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021;74.
21. Delmonte OM, Bergerson JR, Burbelo PD, Durkee-Shock JR, Dobbs K, Bosticardo M, et al. Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. J Clin Immunol. 2021;148(5):1192-7.
22. Pulvirenti F, Fernandez Salinas A, Milito C, Terreri S, Piano Mortari E, Quintarelli C, et al. B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies. Cells. 2021;10(11):2915.
23. Di Fusco M, Moran MM, Cane A, Curcio D, Khan F, Malhotra D, et al. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Eco. 2021;24(1):1248-60.
24. Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. J Clin Immunol. 2022;149(3):907-11. e3.
25. Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L, Li H, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. 2022;22(1):1584.
26. Seidel MG, Kindle G, Gathmann B, Quinti I, Buckland M, van Montfrans J, et al. The European Society for Immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity. J Clin Immunol. 2019;7(6):1763-70.
27. Zeng T, Lu Y, Zhao Y, et al. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts. Respir Res. 2023;24(1):246.
28. Salinas AF, Mortari EP, Terreri S, Quintarelli C, Pulvirenti F, Di Cecca S, et al. SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best. J Clin Immunol. 2021;41:1709-22.
29. Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R, Almendro-Vázquez P, Carretero O, Gil-Etayo FJ, et al. Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency. J Clin Immunol. 2022;42(2):240-52.
30. Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850.
31. Gernez Y, Murugesan K, Cortales CR, Banaei N, Hoyte L, Pinsky BA, et al. Immunogenicity of a third COVID-19 messenger RNA vaccine dose in primary immunodeficiency disorder patients with functional B-cell defects. J Allergy Clinical Immunol. 2022;10(5):1385-8. e2.
32. Goda V, Kriván G, Kulcsár A, Gönczi M, Tasnády S, Matula Z, et al. Specific antibody and the T-cell response elicited by BNT162b2 boosting after two ChAdOx1 nCoV-19 in common variable immunodeficiency. Front Immunol. 2022;13:907125.
33. Nourizadeh M, Feizabadi E, Mirmoghtadaei M, Mohammadi A, Fazlollahi MR, Moradi L, et al. Antibody production after COVID-19 vaccination in patients with inborn errors of immunity. 2023;20(4):400-9.
34. Squire J, Joshi A. Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency. Annals Allergy Asthma Immunol. 2021;127(3):383-4.
35. Delmonte OM, Castagnoli R, Notarangelo LD. COVID-19 and inborn errors of immunity. Physiology. 2022;37(6):290-301.
36. Shin JJ, Par-Young J, Unlu S, McNamara A, Park H-J, Shin MS, et al. Defining clinical and immunological predictors of poor immune responses to COVID-19 mRNA vaccines in patients with primary antibody deficiency. J Clin Immunol. 2022;42(6):1137-50.
| Files | ||
| Issue | Vol 23 No 2 (2024) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijaai.v23i2.15322 | |
| Keywords | ||
| Antibody deficiency Booster COVID-19 Inborn errors of immunity Primary immunodeficiency Sinopharm vaccine Vaccination | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Movahedi M, Movahedi M, Parvaneh N, Abolhassani H, Mahdavi M, Mosavikhorshidi M, Alizadeh F, Shokri M, Kalantari A. Antibody Response Before and After the Booster Dose of Inactivated Corona Vaccine in Antibody Deficient Patients. Iran J Allergy Asthma Immunol. 2024;23(2):158-167.
